Dr. David Lubaroff, Professor Emeritus, Emeritus Professor of Urology has received a UIRF GAP award of $75,000 to assist in advancing his prime-boost prostate cancer treatment method toward commercialization. The GAP project will confirm pervious positive research results, and complete several other critical proof of concept experiments. Successful completion of this project will enable licensing the IP to Ohana Vaccines, an early stage UIVentures startup.
This commercialization funding competition is designed to expand the commercialization of UI technologies. Funds are available to support the development of innovations with commercial potential through a range of stages in technology development, from initial concept, through proof of concept, to licensing and commercialization.
Launched in 2007, the GAP Funding Program helps close the distance between a brilliant idea and a commercially viable outcome. It’s goal is to ‘de-risk’ an invention so it might be more attractive for further commercialization funding or private investment or licensing to an existing company, or generate new intellectual property around which a new venture can be formed.
Pre-proposals will be accepted between June 1 - July 31, 2015. Full proposals (by invitation only) will be accepted July 1 - August 31, 2015.